EFTA00598607Set 9
2014-07-2313p8,093w
were driven by upside Tecfidera Biotechnology / United Stales of America
($144M vs cons), Tysabri ($91M cons, incl. a lx $54M
Shr price. close (Jul 22. 2014) $303.67
or $0.15 catch ... accelerate share gains which should continue to keep
franchise revs flat Y/Y. And on Tysabri, underlying
trends have turned with +3-4% Y/Y vol incr. We have
raised our Tysabri ... more important of the two LINGO datasets, significant
catalysts remain incl. Alzheimer's (2H14), Tysabri in
SPMS (mid-2015), STX-100, Neublastin and Lupus.
Guidance points to strong underlying growth
https://www.justice.gov/epstein/files/DataSet%209/EFTA00598607.pdf
EFTA01199408Set 9
2014-07-2313p8,089w
were driven by upside Tecfidera Biotechnology f United Stales of America
($144M vs cons), Tysabri ($91M cons, incl. a lx $54M
Shr price. close ... accelerate share gains which should continue to keep
franchise revs flat Y/Y. And on Tysabri, underlying
trends have turned with +3-4% Y/Y vol incr. We have
raised our Tysabri ... more important of the two LINGO datasets, significant
catalysts remain incl. Alzheimer's (2H14), Tysabri in
SPMS (mid-2015), STX-100, Neublastin and Lupus.
Guidance points to strong underlying growth
https://www.justice.gov/epstein/files/DataSet%209/EFTA01199408.pdf